Advanced Breast Cancer Outcome Improved with Femara, Ribociclib Combination

Advanced Breast Cancer Outcome Improved with Femara, Ribociclib Combination
Combining Norvartis‘ CDK4/6 inhibitor ribociclib with Femara (letrozole) may be a promising first-line therapy for hormone receptor (HR)-positive breast cancer patients, according to recent data from a Phase 3 clinical trial. The results, recently presented at the European Society for Medical Oncology (ESMO) 2016 Congress, Oct. 7-11, in Copenhagen, show that the combination induced a 44 percent

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *